Agilent Technologies Operating Income Over Time
| A Stock | USD 128.88 0.12 0.09% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Agilent Technologies Performance and Agilent Technologies Correlation. Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agilent Technologies. If investors know Agilent will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Agilent Technologies assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Quarterly Earnings Growth 0.245 | Dividend Share 0.992 | Earnings Share 4.62 | Revenue Per Share | Quarterly Revenue Growth 0.094 |
The market value of Agilent Technologies is measured differently than its book value, which is the value of Agilent that is recorded on the company's balance sheet. Investors also form their own opinion of Agilent Technologies' value that differs from its market value or its book value, called intrinsic value, which is Agilent Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agilent Technologies' market value can be influenced by many factors that don't directly affect Agilent Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Agilent Technologies' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Agilent Technologies represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Agilent Technologies' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare Agilent Technologies and related stocks such as Vir Biotechnology, Prime Medicine Common, and Ginkgo Bioworks Holdings Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| VIR | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (81.5 M) | (118.7 M) | (178 M) | (297 M) | 420.8 M | 833.1 M | (684.3 M) | (587.2 M) | (528.4 M) | (502 M) |
| DNA | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (71.6 M) | (137 M) | (1.8 B) | (2.2 B) | (864.4 M) | (559.8 M) | (503.8 M) | (529 M) |
| REPL | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (9.6 M) | (19.2 M) | (30.9 M) | (56.2 M) | (82.8 M) | (121.5 M) | (177.1 M) | (234.8 M) | (261.6 M) | (235.5 M) | (223.7 M) |
| IOVA | (57.1 K) | (21.2 M) | (8.1 M) | (22.6 M) | (12 M) | (27.9 M) | (53.6 M) | (92.9 M) | (128.3 M) | (206.9 M) | (261.9 M) | (342.7 M) | (398.9 M) | (460.6 M) | (395.3 M) | (355.8 M) | (338 M) |
| KURA | (33.6 K) | (20.5 K) | (23.4 K) | (22.3 K) | (11.8 M) | (23.9 M) | (28.4 M) | (36.1 M) | (62.9 M) | (67.5 M) | (91.9 M) | (131.3 M) | (139.9 M) | (165.8 M) | (193.2 M) | (173.9 M) | (165.2 M) |
| TYRA | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (9.3 M) | (26.3 M) | (58.9 M) | (79.9 M) | (104.2 M) | (93.8 M) | (89.1 M) |
| BCAX | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (37.7 M) | (39.9 M) | (82.4 M) | (74.2 M) | (77.9 M) |
| LENZ | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (29 K) | (13.5 M) | (60.4 M) | (10.5 M) | (72.4 M) | (58.6 M) | (52.7 M) | (55.4 M) |
Agilent Technologies and related stocks such as Vir Biotechnology, Prime Medicine Common, and Ginkgo Bioworks Holdings Operating Income description
Operating Income is the amount of profit realized from Agilent Technologies operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Agilent Technologies is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Agilent Technologies | A |
| Classification | Healthcare |
| Business Address | 5301 Stevens Creek |
| Exchange | New York Stock Exchange |
USD 128.88
Check out Agilent Technologies Performance and Agilent Technologies Correlation. For information on how to trade Agilent Stock refer to our How to Trade Agilent Stock guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Agilent Technologies technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.